Enanta Pharmaceuticals Inc (ENTA)

[pollyvonwog]

I was being facetious about baird mainly commenting on how silly their "downgrade" was. :)

To you your points, yes while no P3s around the corner, there are still multiple catalysts for ENTA before year end other than approval of the 3 DAA regimen: EDP 239 data/trials starting, more info the 2-DAA regimen with ABBV, ENTA selecting nuc to move forward. All told, I think ENTA certainly has room to double from here (a double here is around $1.5b cap) and as you mentioned, their strong cash position and future revenues should limit the downside.